1 Aug 2022

(11 votes)

One of the recipes to fight melanoma is to approach virotherapy, which is mainly based on an oncolytic nonpathogenic virus ECHO-7. The drug was discovered in 1950–60s in Riga, Latvia and became known as Rigvir®.

How Viral Therapy For Melanoma Treatment Works: Painless Intramuscular Injections With Fever As The Only Possible Side Effect

Since its invention, numerous clinical tests have been conducted showing that Virotherapy is able to destroy certain cancer cells. Melanoma patients were the first ones to benefit from the treatment. On top of that, over the years research on Rigvir® injections (Virotherapy) has also demonstrated its capacity to fight melanoma effectively:

Rigvir® is stored in vials in cold environments. After the drug gets injected into the muscle, it then quickly identifies cancer cells, penetrates into them, and destroys them from the inside. Unlike other types of treatment, virotherapy doesn’t affect healthy cells that surround the tumor. A slight increase in body temperature lasting up to 3 days has been registered as the only side effect of Rigvir® so far.

You can also watch the video to visualize how Rigvir therapy for melanoma takes place:

Why You Should Visit Latvia For Melanoma Virus Treatment And What Documents You Have To Provide To Have Your Case Evaluated By Experienced Team Remotely Within 3 Working Days And At No Charge

Before we answer the question “Where can I get Virotherapy® if I live in Australia/New Zealand/South Africa or elsewhere?”, we have to cover the registration issue. There are only 3 countries in the world that have officially recognized Rigvir® as being an effective drug against cancer: Latvia (2004), Georgia (2015), and Armenia (2016). Nevertheless, it doesn’t mean you can’t have it legally in other countries.

There’re number of reasons to visit Latvia for melanoma virus treatment:

  1. The specialists there have managed to treat more than 3,000 cancer patients over the last 15 years. Of course, they’ve seen a log of different cases and know how to deal with cancer at all stages.
  2. They provide free case evaluation within 48–72 hours. Time is of the greatest value when you have cancer, and the doctors there understand it. They don’t want to waste your time, that’s why before coming to Latvia, you’ll be asked to provide several medical records for the team to review them and give you the feedback — if you’re eligible for Rigvir® or not.
  3. The clinic in Latvia (European Union) is really eager to help you by applying holistic approach towards your treatment. In addition to Virotherapy, you can be offered dendritic cell vaccination, CIK-injections and other therapies. If some of them sound unfamiliar, no need to Google it as we’ll tell in you detail what these therapies do later in this article.
  4. The price of the treatment really matters. In Latvia, 7-day treatment starts from 6,000 EUR (6,000 USD), including accommodation and nutrition.

To perform the assessment of your health condition the medical team from ny will request the following medical documents:

  • Recent full blood count (maximum standing of 2 weeks) with White Blood Cells (WBC) indicated
  • Computed Tomography (CT) and Magnetic Resonance Imaging (MRI) – some radiological documents
  • Histopathological and cytological records
  • Epicrisis
  • Biochemical analyses for creatinine, alanine transferase (ALT).

Normally, the evaluation process of melanoma cancer cases takes up to three business days after which the patient coordinator informs you whether you qualify for Virotherapy and provides further step-by-step instructions.

To have your case evaluated, please, press the button and fill in the form. Double-check your contact details for our team to reach you as soon as the results are ready.

7 Days In Latvia for Melanoma Rigvir Therapy Include Virotherapy Injections, Airport Transfers, Patient Care Available 24/7, Accommodation, Nutrition And Complex Body Treatment

A treatment program lasts one week, beginning on your arrival to Latvia. The English-speaking driver meets you at the International Airport and transfers to the clinic. There you’ll be tested whether you are allergic to Virotherapy (Rigvir injections). The treatment process starts with non-stop engagement of oncologist, immunologist, and other medical and administrative personnel. The package includes:

  • Daily consultations with you oncologist
  • Rigvir® injections
  • 24/7 support by medical and administrative personnel
  • Personalized nutrition plan, including organic food and vegetarian diet if you don’t eat meat
  • Comfortable accommodation, Wi-Fi facilities and so on.
  • Several sessions with acupuncture specialist, physiotherapist, etc.
melanoma treatment clinicskin cancer ClinicAmber Life Cancer ClinicAmber Life Cancer Clinicmelanoma alternative treatment

Rigvir clinical use in battling melanoma:

Late stage melanoma - 3-year survival rate of 57-84% and a 5-year survival rate of 44-66% [1]

Between 1968 and 2004, the year of Rigvir® national registration, over 700 patients suffering from late-stage melanoma, gastric and gastrointestinal cancer were involved in clinical studies with the medicine. The results obtained have shown the following:

  • The 3-year survival rate for melanoma patients treated with surgery only was 46–58%, while patients that were also treated with Rigvir® had a 3-year survival rate of 57–84% and a 5-year survival rate of 44–66%
  • The 3- and 5-year survival rate for ocular melanoma patients made 90% and 70%, respectively [1]

Early stage melanoma - significantly prolongs survival in early-stage melanoma patients without any side effect [2]

Malignant melanoma, one of the most aggressive skin cancers, is strongly resistant to chemotherapy and radiotherapy while demonstrating high vulnerability to Rigvir®. The clinically proven study was described in October 2015 in Melanoma Research, a peer-reviewed medical journal:
“An oncolytic, nonpathogenic ECHO-7 virus adapted for melanoma that has not been genetically modified (Rigvir®)is approved and registered for virotherapy in Latvia since 2004… These results indicate that the patients treated with Rigvir® had a 4.39–6.57-fold lower mortality than those under observation… In conclusion, Rigvir® significantly prolongs survival in early-stage melanoma patients without any side effect”. [2]

Stage IV melanoma with metastases - the patients described here were diagnosed 3.5, 7.0, and 6.6 years ago, and their condition has improved and been stable for over 1.5, 6.5, and 4 years, respectively [3]

The findings on three case studies including patients diagnosed with stage IV melanoma with metastases, stage IIIA small cell lung cancer, and stage 4 histiocytic sarcoma were published in July 2016 in APMIS (Acta Pathologica, Microbiologica et Immunologica Scandinavica), a medical journal:
“All patients started Rigvir® treatment within a few months after being diagnosed and are currently continuing Rigvir® treatment… Using current standard treatments, the survival of patients with the present diagnoses is low. In contrast, the patients described here were diagnosed 3.5, 7.0, and 6.6 years ago, and their condition has improved and been stable for over 1.5, 6.5, and 4 years, respectively. These observations suggest that virotherapy using Rigvir® can successfully be used in long-term treatment of patients with melanoma stage IV M1c, small cell lung cancer stage IIIA, and histiocytic sarcoma stage IV...” [3]

Stage IIIB melanoma - the patient has experienced only one more disease progression episode in May 2015 and has been stable for over 60 months [4]

“A female patient was diagnosed with stage IIIB melanoma in December 2012, over 9.4 years ago. After the first excision and re-excision, the patient had several recurrences and disease progressions. After the patient had received surgical treatment in 2014, Rigvir treatment started. Since then, the patient has experienced only one more disease progression episode in May 2015 and has been stable for over 60 months. The patient has not received any other treatment than surgery and Rigvir injections. No severe adverse events have been reported during Rigvir treatment.” [4]

The melanoma virus therapy package starts from 6,000 EUR (6,000 USD), and the price depends on the number of therapies included. After completing the package at the end of the week, you will receive recommendations on how to maintain the virotherapy results, nutrition plan, etc.

If you would like to find out whether you or the one your love qualifies for virotherapy for melanoma, please fill in the form on the right (available in desktop version) or press the button below.

Nadine (theUK) with metastasized malignant melanoma since 1999:

“...I can still play with my children”*

*Results may vary

Jane from the US with with ocular melanoma:

“...I chose not to do the conventional therapy in the United States…And the doctor that did my blood test in the United States was astounded, he couldn’t believe it, he hadn’t seen that...”*

*Results may vary

Zane from Latvia with melanoma stage 1:

“I hadn’t heard anything about Rigvir. I expected my hair would fall out and that I would lose lots of weight. I’m very proud that after using this medication I gave birth to a healthy baby”*

*Results may vary

List of References

  1. “Echovirus-mediated biotherapy for malignant tumours: 40 years of investigation” - Brūvere, R., O., Heisele A. Ferdats, A. Rupais, and A. Muceniece. Acta medica Lituanica, 2002. Suppl. 9: p. 97-100. https://www.virotherapy.com/wp-content/uploads/2012/10/40-years-of-investigation.pdf
  2. “Adapted ECHO-7 Virus RigVir Immunotherapy (oncolytic Virotherapy) Prolongs Survival in Melanoma Patients after Surgical Excision of the Tumour in a Retrospective Study.” - Doniņa, Simona; Strēle, Ieva; Proboka, Guna; Auziņš, Jurgis; Alberts, Pēteris; Jonsson, Björn; Venskus, Dite; Muceniece, Aina. Melanoma Research: October 2015 - Volume 25 - Issue 5 - p 421–426. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4560272/
  3. “Long-term treatment with the oncolytic ECHO-7 virus Rigvir of a melanoma stage IV M1c patient, a small cell lung cancer stage IIIA patient, and a histiocytic sarcoma stage IV patient-three case reports” - Alberts, P., E. Olmane, L. Brokāne, Z. Krastiņa, M. Romanovska, K. Kupčs, S. Isajevs, G. Proboka, R. Erdmanis, J. Nazarovs, and D. Venskus. APMIS, 2016. 124(10): p. 896-904. https://onlinelibrary.wiley.com/doi/10.1111/apm.12576
  4. “A progressive stage IIIB melanoma treated with oncolytic ECHO-7 virus: A case report” - Vladimirs Sorokins, Andra Tilgase, Evija Olmane, Sergejs Isajevs, Tatjana Zablocka, Agnija Rasa, Pēteris Alberts published June 23, 2020. https://journals.sagepub.com/doi/full/10.1177/2050313X20934978